Sequana raises $9.3M for fluid pump implant; Teleflex introduces new anesthesia mask;

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Silk Road reels in $57M to commercialize its system for stroke prevention. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Roche notches molecular diagnostics sales win; Veracyte CEO lambastes CMS pricing proposals. Report | Follow @EmilyWFierce

> Sequana Medical raised CHF 9 million ($9.3M) as an extension to a Series C round to gain FDA approval for its implantable pump system to manage excess fluid in the body. More

> Teleflex ($TFX) has introduced its single-use laryngeal mask for anesthesia delivery, LMA Protector Airway. It's designed to reduce airway-related complications. More

> Devon Medical Product has launched its Deep Vein Thrombosis (DVT) Prevention Therapy Device, a pneumatic compression sleeve used postoperatively. More

Biotech News

@FierceBiotech: Merrimack wins expedited FDA OK for pancreatic cancer drug Onivyde. Report | Follow @FierceBiotech

@JohnCFierce: The $NK market cap is down to a meager $873M, debuted at $2.6B -- Still too much? Soon-Shiong magic sparkles not so shiny? | Follow @JohnCFierce

@DamianFierce: So I guess $SHPG's Lumena buyout didn't go so well. Story | More | Follow @DamianFierce

> Amgen's T-Vec inches toward EU approval for melanoma. Report

> Spectrum tanks after the FDA rejects its blood cancer drug. Article

Pharma News

@FiercePharma: Asia's dengue epidemic highlights race for treatment, vaccine options. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Japan's says its mAb work with means a need for a $309M API plant expansion. FiercePharmaManufacturing news | Follow @EricPFierce

@CarlyHFierce: : We did an episode of @FierceBiotech Radio on biopharma's wacky Wednesday. More | Follow @CarlyHFierce

> Novartis wins European recs for a pair of new Cosentyx uses. Item

> Shire's not giving up on target Baxalta, it says amid Q3 beat. Article